Circadian Dysregulation in Parkinson's Disease

Aleksandar Videnovic, Diego Golombek, Aleksandar Videnovic, Diego Golombek

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder that affects over one million individuals in the US alone. PD is characterized by a plethora of motor and non-motor manifestations, resulting from a progressive degeneration of dopaminergic neurons and disbalance of several other neurotransmitters. A growing body of evidence points to significant alterations of the circadian system in PD. This is not surprising given the pivotal role that dopamine plays in circadian regulation as well as the role of circadian influences in dopamine metabolism. In this review we present basic and clinical investigations that examined the function of the circadian system in PD.

Keywords: Parkinson’s; circadian; clock genes; dopamine; sleep.

References

    1. Agostino P.V., Do Nascimento M., Bussi I.L. Circadian modulation of interval timing in mice. Brain Res. 2011;1370:154–163.
    1. Agostino P.V., Golombek D.A., Meck W.H. Unwinding the molecular basis of interval and circadian timing. Front. Integr. Neurosci. 2011;5:64.
    1. Alves G., Forsaa E.B., Pedersen K.F. Epidemiology of Parkinson's disease. J. Neurol. 2008;255(Suppl 5):18–32.
    1. Arias-Vera J.R., Mansoor G.A., White W.B. Abnormalities in blood pressure regulation in a patient with Parkinson's disease. Am. J. Hypertens. 2003;16(7):612–613.
    1. Aziz N.A., Pijl H., Frolich M. Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease. J. Neuroendocrinol. 2011;23(6):519–524.
    1. Aziz N.A., Pijl H., Flilich M. Leptin, adiponectin, and resistin secretion and diurnal rhythmicity are unaltered in Parkinson's disease. Mov. Disord. 2011;26(4):760–761.
    1. Baier P.C., Trenkwalder C. Circadian variation in restless legs syndrome. Sleep Med. 2007;8(6):645–650.
    1. Ben V., Bruguerolle B. Effects of bilateral striatal 6-OHDA lesions on circadian rhythms in the rat: a radiotelemetric study. Life Sci. 2000;67(13):1549–1558.
    1. Bolitho S.J., Naismith S.L., Rajaratnam S.M. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014;15(3):342–347.
    1. Bonuccelli U., Del Dotto P., Lucetti C. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Clin. Neuropharmacol. 2000;23(1):28–33.
    1. Boulamery A., Simon N., Vidal J. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol. Int. 2010;27(2):251–264.
    1. Breen D.P., Vuono R., Nawarathna U. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014;71(5):589–595.
    1. Brown S.A., Schmitt K., Eckert A. Aging and circadian disruption: causes and effects. Aging. 2011;3(8):813–817.
    1. Burns R.S., Chiueh C.C., Markey S.P. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 1983;80(14):4546–4550.
    1. Bussi I.L., Levin G., Golombek D.A. Involvement of dopamine signaling in the circadian modulation of interval timing. Eur. J. Neurosci. 2014;40(1):2299–2310.
    1. Cai Y., Liu S., Sothern R.B. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. Eur. J. Neurol. 2010;17(4):550–554.
    1. Castaneda T.R., de Prado B.M., Prieto D. Circadian rhythms of dopamine, glutamate and GABA in the striatum and nucleus accumbens of the awake rat: modulation by light. J. Pineal Res. 2004;36(3):177–185.
    1. Comella C.L. Sleep disorders in Parkinson's disease: an overview. Mov. Disord. 2007;22(S17):S367–S373.
    1. Crabtree D.M., Zhang J. Genetically engineered mouse models of Parkinson's disease. Brain Res. Bull. 2012;88(1):13–32.
    1. Czeisler C.A., Allan J.S., Strogatz S.H. Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science. 1986;233(4764):667–671.
    1. Devos D., Kroumova M., Bordet R. Heart rate variability and Parkinson's disease severity. J. Neural Transm. 2003;110(9):997–1011.
    1. Divito C.B., Steece-Collier K., Case D.T. Loss of VGLUT3 produces circadian-dependent hyperdopaminergia and ameliorates motor dysfunction and L-dopa-mediated dyskinesias in a model of Parkinson's disease. J. Neurosci. 2015;35(45):14983–14999.
    1. Dorsey E.R., Constantinescu R., Thompson J.P. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386.
    1. Ejaz A.A., Sekhon I.S., Munjal S. Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson's disease. Eur. J. Intern. Med. 2006;17(6):417–420.
    1. Factor S.A., Weiner W.J. Sleep benefit' in Parkinson's disease. Neurology. 1998;50:1514e5.
    1. Fertl E., Auff E., Doppelbauer A. Circadian secretion pattern of melatonin in Parkinson's disease. J. Neural Transm. Park Dis. Dement. Sect. 1991;3(1):41–47.
    1. Fertl E., Auff E., Doppelbauer A. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of L-dopa. J. Neural Transm. Park Dis. Dement. Sect. 1993;5(3):227–234.
    1. Fifel K., Cooper H.M. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease. Neurobiol. Dis. 2014;71:359–369.
    1. Fifel K., Piggins H., Deboer T. Modeling sleep alterations in Parkinson's disease: how close are we to valid translational animal models? Sleep. Med. Rev. 2016;25:95–111.
    1. Fliers E., Swaab D.F., Pool C.W. The vasopressin and oxytocin neurons in the human supraoptic and paraventricular nucleus; changes with aging and in senile dementia. Brain Res. 1985;342(1):45–53.
    1. Golombek D.A., Bussi I.L., Agostino P.V. Minutes, days and years: molecular interactions among different scales of biological timing. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014;369(1637):20120465.
    1. Gravotta L., Gavrilla L.A., Hood S. Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. J. Mol. Neurosci. 2011;45(2):162–171.
    1. Haapaniemi T.H., Pursiainen V., Korpelainen T. Ambulatory ECG and analysis of heart rate variability in Parkinson's disease. J Neurol. Neurosurg. Psychiatry. 2001;70(3):305–310.
    1. Hineno T., Mizobuchi M., Hiratani K. Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs. Brain Res. 1992;580(1-2):92–99.
    1. Hogl B.E., Gomez-Arevalo G., Garcia S. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology. 1998;50:1332e9.
    1. Hood S., Cassidy P., Cossette M.P. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J. Neurosci. 2010;30(42):14046–14058.
    1. Hyacinthe C., Barraud Q., Bezard E. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. Neurobiol. Dis. 2014;63:20–24.
    1. Ikeda E., Matsunaga N., Kakimoto K. Molecular mechanism regulating 24-hour rhythm of dopamine D3 receptor expression in mouse ventral striatum. Mol. Pharmacol. 2013;83(5):959–967.
    1. Jagmag S.A., Tripathi N., Shukla D. Evaluation of Models of Parkinson's Disease. Front. Neurosci. 2015;9:503.
    1. Johnston T.M., Fox S.H. Symptomatic models of Parkinson's disease and L-dopa-induced dyskinesia in non-human primates. Curr. Top. Behav. Neurosci. 2015;22:221–235.
    1. Ju Y.E., Lucey B.P., B. P, Holtzman D.M. Sleep and Alzheimer disease pathology-a bidirectional relationship. Nat. Rev. Neurol. 2014;10(2):115–119.
    1. Kafka M.S., Benedito M.A., Roth R.H. Circadian rhythms in catecholamine metabolites and cyclic nucleotide production. Chronobiol. Int. 1986;3(2):101–115.
    1. Kallio M., Haapaniemi T., Turkka J. Heart rate variability in patients with untreated Parkinson's disease. Eur. J. Neurol. 2000;7(6):667–672.
    1. Kallio M., Suominen K., Haapaniemi T. Nocturnal cardiac autonomic regulation in Parkinson's disease. Clin. Auton. Res. 2004;14(2):119–124.
    1. Klerman E.B., Rimmer D.W., D.J. Nonphotic entrainment of the human circadian pacemaker. Am. J. Physiol. 1998;274(4 Pt 2):R991–R996.
    1. Kudo T., Loh D.H., Truong D. Circadian dysfunction in a mouse model of Parkinson's disease. Exp. Neurol. 2011;232(1):66–75.
    1. Laloux C., Derambure P., Houdayer E. Effect of dopaminergic substances on sleep/wakefulness in saline – and MPTP-treated mice. J. Sleep Res. 2008;17(1):101–110.
    1. Li S.X., Liu L.J., Jiang W.G. Morphine withdrawal produces circadian rhythm alterations of clock genes in mesolimbic brain areas and peripheral blood mononuclear cells in rats. J. Neurochem. 2009;109(6):1668–1679.
    1. Mamelak M. Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis. J. Geriatr. Psychiatry Neurol. 1997;10(1):29–32.
    1. Mastrocola C., Vanacore N., Giovani A. Twenty-four-hour heart rate variability to assess autonomic function in Parkinson's disease. Acta Neurol. Scand. 1999;99(4):245–247.
    1. Mattam U., Jagota A. Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson’s disease male Wistar rat model and effect of melatonin administration. Biogerontology. 2015;16(1):109–123.
    1. Mattis J., Sehgal A. Circadian rhythms, sleep, and disorders of aging. Trends Endocrinol. Metab. 2016;27(4):192–203.
    1. McDowell K., Chesselet M.F. Animal models of the non-motor features of Parkinson's disease. Neurobiol. Dis. 2012;46(3):597–606.
    1. McDowell K.A., Shin D., Roos K.P. Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein. J. Parkinsons Dis. 2014;4(3):531–539.
    1. McEnany G.W., Lee K.A. Effects of light therapy on sleep, mood, and temperature in women with nonseasonal major depression. Issues Ment. Health Nurs. 2005;26(7):781–794.
    1. Mendoza J., Challet E. Circadian insights into dopamine mechanisms. Neuroscience. 2014;282:230–242.
    1. Merello M., Hughes A., Colosimo C. Sleep benefit in Parkinson's disease. Mov. Disord. 1997;12:506e8.
    1. Mihci E., Kardelen F., Dora B. Orthostatic heart rate variability analysis in idiopathic Parkinson's disease. Acta Neurol. Scand. 2006;113(5):288–293.
    1. Morton A.J., Wood N.I., Hastings M., H. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 2005;25(1):157–163.
    1. Natsubori A., Honma K., Honma S. Dual regulation of clock gene Per2 expression in discrete brain areas by the circadian pacemaker and methamphetamine-induced oscillator in rats. Eur. J. Neurosci. 2014;39(2):229–240.
    1. Nutt J.G., Woodward W.E., Carter J.H. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J. Neurol. Neurosurg. Psychiatry. 1989;52(4):481–487.
    1. Parekh P.K., Ozburn A.R., McClung C.A. Circadian clock genes: effects on dopamine, reward and addiction. Alcohol. 2015;49(4):341–349.
    1. Pathak A., Senard J.M. Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology and management. Expert Rev. Neurother. 2006;6(8):1173–1180.
    1. Paus S., Schmitz-Hubsch T., Wullner M. Bright light therapy in Parkinson's disease: a pilot study. Mov. Disord. 2007;22(10):1495–1498.
    1. de Pedro Cuesta J. Studies on the prevalence of paralysis agitans by tracer methodology. Acta Neurol. Scand. 1987;(Suppl. 112):1–106.
    1. de Pedro-Cuesta J., Stawiarz L. Parkinson's disease incidence: magnitude, comparability, time trends. Acta Neurol. Scand. 1991;84(5):382–388.
    1. Piccini P., Del Dotto P., Pardini C. Diurnal worsening in Parkinson patients treated with levodopa. Rev. Neurol. 1991;61(6):219–224.
    1. Placidi F., Izzi F., Romigi A. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. J. Neurol. 2008;255(7):1032–1037.
    1. Poceta J.S., Parsons L., Engelland S. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med. 2009;10(1):129–133.
    1. Porter B., Macfarlane R., Walker R. The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease. Eur. J. Neurol. 2008;15(1):50–54.
    1. Pungor K., Papp M., Kekesi K. A novel effect of MPTP: the selective suppression of paradoxical sleep in cats. Brain Res. 1990;525(2):310–314.
    1. Pursiainen V., Haapaniemi T.H., Korpelainen J.T. Circadian heart rate variability in Parkinson's disease. J. Neurol. 2002;249(11):1535–1540.
    1. Riemersma-van der Lek R.F., Swaab D.F., Twisk J. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299(22):2642–2655.
    1. Roybal K., Theobold D., Graham A. Mania-like behavior induced by disruption of CLOCK. Proc. Natl. Acad. Sci. USA. 2007;104:6406–6411.
    1. Seron-Ferre M., Torres-Farfan C., Forcelledo M.L. The development of circadian rhythms in the fetus and neonate. Semin. Perinatol. 2001;25(6):363–370.
    1. Shumay E., Fowler J.S., Wang G.J. Repeat variation in the human PER2 gene as a new genetic marker associated with cocaine addiction and brain dopamine D2 receptor availability. Transl. Psychiatry. 2012;2:e86.
    1. Sleipness E.P., Sorg B.A., Jansen H.T. Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. Brain Res. 2007;1129(1):34–42.
    1. Struck L.K., Rodnitzky R.L., Dobson J.K. Circadian fluctuations of contrast sensitivity in Parkinson’s disease. Neurology. 1990;40(3 Pt 1):467–470.
    1. Suzuki K., Miyamoto T., Miyamoto M. Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease. Neuropsychobiology. 2007;56(4):172–179.
    1. Taylor T.N., Caudle W.M., Shepherd K.R. Nonmotor symptoms of Parkinson’s disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 2009;29(25):8103–8113.
    1. Terman M., Terman J.S. Bright light therapy: side effects and benefits across the symptom spectrum. J. Clin. Psychiatry. 1999;60(11):799–808.
    1. Terman M., Terman J.S. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectr. 2005;10(8):647–663.
    1. van Gilst M.M., Bloem B.R., Overeem S. “Sleep benefit” in Parkinson’s disease: a systematic review. Parkinsonism Relat. Disord. 2013;19(7):654–659.
    1. van Hilten B., Hoff J.I., Middelkoop H.A. Sleep disruption in Parkinson’s disease. Assessment by continuous activity monitoring. Arch. Neurol. 1994;51(9):922–928.
    1. van Hilten J.J., Middelkoop H.A., Kerkhof G.A. A new approach in the assessment of motor activity in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry. 1991;54(11):976–979.
    1. van Hilten J.J., Hoogland G., van der Velde E.A. Diurnal effects of motor activity and fatigue in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry. 1993;56(8):874–877.
    1. van Hilten J.J., Kabel J.F., Middelkoop H.A. Assessment of response fluctuations in Parkinson’s disease by ambulatory wrist activity monitoring. Acta Neurol. Scand. 1993;87(3):171–177.
    1. van Hilten J.J., Weggeman M., van der Velde E.A. Sleep, excessive daytime sleepiness and fatigue in Parkinson’s disease. J. Neural Transm. Park Dis. Dement. Sect. 1993;5(3):235–244.
    1. Verbaan D., van Rooden S.M., Visser M. Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov. Disord. 2008;23(1):35–41.
    1. Vezoli J., Fifel K., Leviel V. Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson’s disease. PLoS One. 2011;6(8):e2395.
    1. Videnovic A., Golombek D. Circadian and sleep disorders in Parkinson’s disease. Exp. Neurol. 2013;24:45–56.
    1. Videnovic A., Willis G.L. Circadian system – a novel diagnostic and therapeutic target in Parkinson’s disease? Mov. Disord. 2016;31(3):260–269.
    1. Videnovic A., Lazar A.S., Barker R.A. “The clock that time us” - circadian rhythms in neurodegenerative disorders. Nat. Rev. Neurol. 2014;10(12):683–693.
    1. Videnovic A., Noble C., Reid K.J. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71(4):463–469.
    1. Whitehead D.L., Davies A.D., Playfer J.R. Circadian rest-activity rhythm is altered in Parkinson’s disease patients with hallucinations. Mov. Disord. 2008;23(8):1137–1145.
    1. Willis G.L., Turner E.J. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol. Int. 2007;24(3):521–537.
    1. Willis G.L., Kelly A.M., Kennedy G.A. Compromised circadian function in Parkinson’s disease: enucleation augments disease severity in the unilateral model. Behav. Brain Res. 2008;193(1):37–47.
    1. Willis G.L., Moore C., Armstrong S.M. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev. Neurosci. 2012;23(2):199–226.
    1. Witkovsky P. Dopamine and retinal function. Doc. Ophthalmol. 2004;108(1):17–40.
    1. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol. Neurobiol. 2001;21(6):605–616.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir